Biomarker discovery for practice of precision medicine in hypopharyngeal cancer: a theranostic study on response prediction of the key therapeutic agents

dc.contributor.authorKawata-Shimamura Yumiko
dc.contributor.authorEguchi Hidetaka
dc.contributor.authorKawabata-Iwakawa Reika
dc.contributor.authorNakahira Mitsuhiko
dc.contributor.authorOkazaki Yasushi
dc.contributor.authorYoda Tetsuya
dc.contributor.authorGrenman Reidar
dc.contributor.authorSugasawa Masashi
dc.contributor.authorNishiyama Masahiko
dc.contributor.organizationfi=korva-, nenä-, ja kurkkutautioppi|en=Otorhinolaryngology - Head and Neck Surgery|
dc.contributor.organizationfi=tyks, vsshp|en=tyks, varha|
dc.contributor.organization-code2607312
dc.converis.publication-id176161949
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/176161949
dc.date.accessioned2022-10-27T11:50:34Z
dc.date.available2022-10-27T11:50:34Z
dc.description.abstract<p><strong>Background: </strong>Hypopharyngeal cancer is a relatively rare malignancy with poor prognosis. Current chemotherapeutic algorithm is still far from personalized medicine, and the identification of the truly active therapeutic biomarkers and/or targets is eagerly awaited.</p><p><strong>Methods: </strong>Venturing to focus on the conventional key chemotherapeutic drugs, we identified the most correlative genes (and/or proteins) with cellular sensitivity to docetaxel (TXT), cisplatin (CDDP) and 5-fluorouracil (5-FU) in the expression levels, through 3 steps approach: genome-wide screening, confirmation study on the quantified expression levels, and knock-down and transfection analyses of the candidates. The probable action pathways of selected genes were examined by Ingenuity Pathway Analysis using a large-scale database, The Cancer Genome Atlas.</p><p><strong>Results: </strong>The first genome-wide screening study derived 16 highly correlative genes with cellular drug sensitivity in 15 cell lines (|R| > 0.8, P < 0.01 for CDDP and 5-FU; |R| > 0.5, P < 0.05 for TXT). Among 10 genes the observed correlations were confirmed in the quantified gene expression levels, and finally knock-down and transfection analyses provided 4 molecules as the most potent predictive markers-AGR2 (anterior gradient 2 homolog gene), and PDE4D (phosphodiesterase 4D, cAMP-specific gene) for TXT; NINJ2 (nerve Injury-induced protein 2); CDC25B (cell division cycle 25 homolog B gene) for 5-FU- in both gene and protein expression levels. Overexpression of AGR2, PDE4D signified worse response to TXT, and the repressed expression sensitized TXT activity. Contrary to the findings, in the other 2 molecules, NINJ2 and CDC25, there observed opposite relationship to cellular drug response to the relevant drugs. IPA raised the potential that each selected molecule functionally interacts with main action pathway (and/or targets) of the relevant drug such as tubulin β chain genes for TXT, DNA replication pathway for CDDP, and DNA synthesis pathway and thymidylate synthetase gene for 5-FU.</p><p><strong>Conclusion: </strong>We newly propose 4 molecules -AGR2, PDE4D,NINJ2 and CDC25B) as the powerful exploratory markers for prediction of cellular response to 3 key chemotherapeutic drugs in hypopharyngeal cancers and also suggest their potentials to be the therapeutic targets, which could contribute to the development of precision medicine of the essential chemotherapy in hypopharyngeal patients.</p>
dc.identifier.jour-issn1471-2407
dc.identifier.olddbid172224
dc.identifier.oldhandle10024/155318
dc.identifier.urihttps://www.utupub.fi/handle/11111/29961
dc.identifier.urlhttps://doi.org/10.1186/s12885-022-09853-1
dc.identifier.urnURN:NBN:fi-fe2022091258422
dc.language.isoen
dc.okm.affiliatedauthorGrenman, Reidar
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3122 Cancersen_GB
dc.okm.discipline3122 Syöpätauditfi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherBMC
dc.publisher.countryUnited Kingdomen_GB
dc.publisher.countryBritanniafi_FI
dc.publisher.country-codeGB
dc.relation.articlenumber779
dc.relation.doi10.1186/s12885-022-09853-1
dc.relation.ispartofjournalBMC Cancer
dc.relation.issue1
dc.relation.volume22
dc.source.identifierhttps://www.utupub.fi/handle/10024/155318
dc.titleBiomarker discovery for practice of precision medicine in hypopharyngeal cancer: a theranostic study on response prediction of the key therapeutic agents
dc.year.issued2022

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
s12885-022-09853-1.pdf
Size:
2.57 MB
Format:
Adobe Portable Document Format